Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Israeli start-up BioLineRx goes public through $50mm IPO

Executive Summary

Israeli specialty pharma BioLineRx has grossed about $50mm through its initial public offering of 28.7mm common shares at $1.74 apiece on the Tel Aviv Stock Exchange. Some of the company's private investors including Teva, Giza Venture Capital, Pitango Venture Capital, and Hadasit bought stock through the IPO.
Deal Industry
  • Biotechnology
    • Antisense, Oligonucleotides
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies